Currently Accruing Clinical Trials

Email: clinicaltrials@theangelesclinic.org or call (310) 231-2150 with questions and referrals.

Click on Name TUMOR TYPE

Phase 1 trials (Any Cancer) • CAR-T • Breast Cancer • Bladder Cancer • Colorectal Cancer • Endometrial Cancer • Esophageal Cancer • Gastric Cancer • Head and Neck Cancer • Hepatocellular Cancer • Lung Cancer • Melanoma (Adjuvant) • Metastatic Melanoma • Ocular Melanoma • Mesothelioma • Ovarian Cancer • Pancreatic Cancer • Prostate Cancer • Renal Cell Carcinoma • Sarcoma • Squamous Cell SKIN

PHASE ONE SOLID TUMORS AND LYMPHOMA

A Study of RO7198457 (personalized vaccine) Single Agent and in Combination With Atezolizumab (antiPD-L1) in Participants With Locally Advanced or Metastatic Tumors [NCT03289962]

Phase 1/2 Study of RTX-240 (4-1BB and IL-15) Monotherapy in Solid Tumors [NCT04372706]

Phase 1, Open-Label, Dose-Escalation Study of ABBV-927 (antiCD40 Agonist) and ABBV-181 (anitPD1) Immunotherapy, in Subjects with Advanced Solid Tumors [NCT02988960]

Phase 1 Study of ABBV-321 in Subjects with Advanced Solid Tumors Associated with Overexpression of the Epidermal Growth Factor Receptor (EGFR) or its Ligands [NCT03234712]

Phase 1/2 Study of ALKS 4230 (Selective IL-2) Administered Subcutaneously as Monotherapy and in Combination With Pembrolizumab (antiPD1) With Advanced Solid Tumors [NCT03861793]

Phase 1 Study to Evaluate the Safety and Tolerability of AB928 (Adenosine Antagonist) with AB122 (antiPD1) Immunotherapy Combinations in Participants with Advanced Malignancies [NCT03629756]

Phase 1 Study of AB154 (TIGIT antibody) Monotherapy and Combination Therapy in Advanced Malignancies [NCT032628677]

Phase 1 study of ASP9801, an Oncolytic Virus, Administered by Intratumoral Injection in Advanced/Metastatic Solid Tumors [NCT03954067]

Phase 1b/2 study of copanlisib (PI3K inhibitor) in combination with nivolumab (PD1 antibody) in Advanced Solid Tumors [NCT03735628]

Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors [NCT03170960]

Phase 1 Study of GSK3359609 (ICOS stimulatory antibody) Alone and in Combination with Anticancer Agents in Advanced Solid Tumors [NCT02723955]

Phase 1/2 Study IMC-C103C (bispecific) as Single Agent or Combination with Atezolizumab (PD-L1 antibody) in HLA-A 0201-Positive Patients with Mage-A4- Positive Cancer [NCT03973333]

Phase 1/2 Study of IMC-F106C (bispecific) as a Single Agent and in Combination with Checkpoint Inhibitors in HLA-A*02:01-Positive Participants with Advanced PRAME-Positive Cancers [NCT04262466]

Phase 1b study of INCMGA00012 (PD-1 antibody) in Combination with Therapies (PI3Kinase, IDO) in Advanced Tumors [NCT03589651]

Phase 1/2 Study of NC318 (Siglec 15 antibody) in Advanced or Metastatic Solid Tumors [NCT03665285]

Phase 1 Study of REGN3767 (anti-LAG-3 mAb) Administered Alone or in Combination with REGN2810 (anti-PD-1 mAb) in Patients with Advanced Malignancies [NCT03005782]

TAPUR - The Targeted Agent and Profiling Utilization Registry (TAPUR) Study [NCT02693535]

Phase 1 study of SGN-CD228A (ANTIBODY DRUG CONJUGATE) in select advanced solid tumors [NCT04042480]

Phase 1 Study of BDB001 (IV TLR agonist) in Combination with Atezolizumab (PD-L1 antibody) in Subjects with Advanced Solid Tumors [NCT04196530]

VE800 Microbiome Therapy and Nivolumab in patients with selected types of advanced or metastatic cancer [NCT04208958]

CAR-T Solid Tumor - Chimeric Antigen

Tmunity Protocol CART-TnMUC1-01 - A phase 1, open-label, multi-center first in human study of TnMUC1-Targeted genetically-modified chimeric antigen receptor T cells in patients with advanced TnMUC1-positive solid tumors and multiple myeloma [NCT04025216]

BREAST CANCER

Phase 1/2 Study of IMC-F106C (bispecific) as a Single Agent and in Combination with Checkpoint Inhibitors in HLA-A*02:01-Positive Participants with Advanced PRAME-Positive Cancers [NCT04262466]

Phase 1 study of SGN-CD228A (ANTIBODY DRUG CONJUGATE) in select advanced solid tumors [NCT04042480]

BLADDER CANCER

Phase 1/2 Study IMC-C103C (bispecific) as Single Agent or Combination with Atezolizumab (PD-L1 antibody) in HLA-A 0201-Positive Patients with Mage-A4- Positive Cancer [NCT03973333]

Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors [NCT03170960]

Phase 1b study of INCMGA00012 (PD-1 antibody) in Combination with Therapies (PI3Kinase, IDO) in Advanced Tumors [NCT03589651]

please see PHASE 1 TRIALS above

COLORECTAL CANCER

Phase 1b/2 study of copanlisib (PI3K inhibitor) in combination with nivolumab (PD1 antibody) in Advanced Solid Tumors [NCT03735628]

Phase 1 study of SGN-CD228A (ANTIBODY DRUG CONJUGATE) in select advanced solid tumors [NCT04042480]

VE800 Microbiome Therapy and Nivolumab in patients with selected types of advanced or metastatic cancer [NCT04208958]

please see PHASE 1 TRIALS above

ENDOMETRIAL CANCER

Phase 1/2 Study of IMC-F106C (bispecific) as a Single Agent and in Combination with Checkpoint Inhibitors in HLA-A*02:01-Positive Participants with Advanced PRAME-Positive Cancers [NCT04262466]

please see PHASE 1 TRIALS above

GASTRIC/ESOPHAGEAL CANCER

Phase 1/2 Study IMC-C103C (bispecific) as Single Agent or Combination with Atezolizumab (PD-L1 antibody) in HLA-A 0201-Positive Patients with Mage-A4- Positive Cancer [NCT03973333]

VE800 Microbiome Therapy and Nivolumab in patients with selected types of advanced or metastatic cancer [NCT04208958]

please see PHASE 1 TRIALS above

HEAD & NECK CANCER

Phase 1b/2 study of copanlisib (PI3K inhibitor) in combination with nivolumab (PD1 antibody) in Advanced Solid Tumors [NCT03735628]

Phase 1 Study of ABBV-321 in Subjects with Advanced Solid Tumors Associated with Overexpression of the Epidermal Growth Factor Receptor (EGFR) or its Ligands [NCT03234712]

Phase 1 Study of GSK3359609 (ICOS stimulatory antibody) Alone and in Combination with Anticancer Agents in Advanced Solid Tumors [NCT02723955]

please see PHASE 1 TRIALS above

HEPATOCELLULAR CANCER (HCC)

Phase 1b/2 study of copanlisib (PI3K inhibitor) in combination with nivolumab (PD1 antibody) in Advanced Solid Tumors [NCT03735628]

Phase 1b study of INCMGA00012 (PD-1 antibody) in Combination with Therapies (PI3Kinase, IDO) in Advanced Tumors [NCT03589651

please see PHASE 1 TRIALS above

LUNG CANCER

Phase 1b/2 study of copanlisib (PI3K inhibitor) in combination with nivolumab (PD1 antibody) in Advanced Solid Tumors [NCT03735628]

Phase 1 study of SGN-CD228A (ANTIBODY DRUG CONJUGATE) in select advanced solid tumors [NCT04042480]
Phase 1 Study of GSK3359609 (ICOS stimulatory antibody) Alone and in Combination with Anticancer Agents in Advanced Solid Tumors [NCT02723955]

Phase 1/2 Study IMC-C103C (bispecific) as Single Agent or Combination with Atezolizumab (PD-L1 antibody) in HLA-A 0201-Positive Patients with Mage-A4- Positive Cancer [NCT03973333]

Phase 1/2 Study of IMC-F106C (bispecific) as a Single Agent and in Combination with Checkpoint Inhibitors in HLA-A*02:01-Positive Participants with Advanced PRAME-Positive Cancers [NCT04262466]

Phase 1 Study of ABBV-321 in Subjects with Advanced Solid Tumors Associated with Overexpression of the Epidermal Growth Factor Receptor (EGFR) or its Ligands [NCT03234712]

please see PHASE 1 TRIALS above

MELANOMA ADJUVANT

KEYNOTE 716 - Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High-risk Stage II Melanoma [NCT03553836]

Phase 2 Randomized Study of Adjuvant Immunotherapy with Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab vs Pembrolizumab Alone after Complete Resection of High-risk Melanoma [NCT03897881]

Phase 3, Randomized, Double-Blind Study of Adjuvant Immunotherapy with Nivolumab (Anti-PD1) versus Placebo after Complete Resection of Stage IIB/C Melanoma [NCT04099251]

METASTATIC MELANOMA

TIL PROTOCOL IOVANCE C-144-01 - Phase 2 Study of Cell Transfer Therapy Using Autologous Tumor Infiltrating Lymphocytes (LN-144) Followed by IL-2 for Treatment of Metastatic Melanoma [NCT02360579]

A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination with Ipilimumab and Nivolumab in Patients with Unresectable Stage III or Stage IV Melanoma [NCT03999749]

MK-3475-02B: Safety and Efficacy of Pemrolizumab in Combination with Investigational Agents [NCT04305054]

Phase 2 study of the efficacy and safety of RO7198457 (personalized vaccine) in combination with pembrolizumab versus pembrolizumab in patients with previously untreated advanced melanoma [NCT03815058]

Parker Institute Protocol PICI0014 - Phase 1b Randomized, Placebo-controlled, Study to Evaluate the Safety, Tolerability and Efficacy of Microbiome Study Intervention Administration in Combination with Anti-PD-1 Therapy in Adult Patients with Unresectable or Metastatic Melanoma [NCT03817125]

A Randomized Phase II Open Platform Study Evaluating the Efficacy and Safety of Novel Spartalizumab (PD-1 Antibody) combinations (LAG-3, c-met) in Previously Treated Unresectable or Metastatic Melanoma [NCT03484923]

Phase 1 study of SGN-CD228A (ANTIBODY DRUG CONJUGATE) in select advanced solid tumors [NCT04042480]

Immunocore IMCgp100-201 - Phase Ib/II Study of IMCgp100 (CD3/GP100 BISPECIFIC) in Combination with Durvalumab (PD-L1 Antibody) or Tremelimumab (CTLA4 Antibody) or Dual Combination Compared to IMCgp100 Alone in Patients with Advanced Melanoma [NCT02535078]

Phase 2 Open-label, Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients with BRAFV600-mutant Melanoma Brain Metastasis [NCT03911869]

Phase 1/2 Study of IMC-F106C (bispecific) as a Single Agent and in Combination with Checkpoint Inhibitors in HLA-A*02:01-Positive Participants with Advanced PRAME-Positive Cancers [NCT04262466]

Phase 1b study of INCMGA00012 (PD-1 antibody) in Combination with Therapies (PI3Kinase, IDO) in Advanced Tumors [NCT03589651]

Phase 1 Study of BDB001 (IV TLR agonist) in Combination with Atezolizumab (PD-L1 antibody) in Subjects with Advanced Solid Tumors [NCT04196530]

VE800 Microbiome Therapy and Nivolumab in patients with selected types of advanced or metastatic cancer [NCT04208958]

please see PHASE 1 TRIALS above

OCULAR MELANOMA

Immunocore IMCgp100-202 A Phase II Randomized Study of IMCgp100 (CD3/GP100 BISPECIFIC) Compared with Investigator’s Choice in Patients with Previously Untreated Advanced Uveal Melanoma [NCT03070392]

Phase 1/2 Study of IMC-F106C (bispecific) as a Single Agent and in Combination with Checkpoint Inhibitors in HLA-A*02:01-Positive Participants with Advanced PRAME-Positive Cancers [NCT04262466]

please see PHASE 1 TRIALS above

MESOTHELIOMA

VE800 Microbiome Therapy and Nivolumab in patients with selected types of advanced or metastatic cancer [NCT04208958]

please see PHASE 1 TRIALS above

OVARIAN CANCER

Phase 1/2 Study IMC-C103C (bispecific) as Single Agent or Combination with Atezolizumab (PD-L1 antibody) in HLA-A 0201-Positive Patients with Mage-A4- Positive Cancer [NCT03973333]

Phase 1/2 Study of IMC-F106C (bispecific) as a Single Agent and in Combination with Checkpoint Inhibitors in HLA-A*02:01-Positive Participants with Advanced PRAME-Positive Cancers [NCT04262466]

please see PHASE 1 TRIALS above

PANCREATIC CANCER

Phase 1 study of SGN-CD228A (ANTIBODY DRUG CONJUGATE) in select advanced solid tumors [NCT04042480]

please see PHASE 1 TRIALS above

PROSTATE CANCER

Parker Institute Protocol PICI0033 – A Multicenter, Exploratory Platform Study to Evaluate Biomarkers and Immunotherapy Combinations for the Treatment of Patients with Metastatic Castration Resistant Prostate Cancer [NCT03835533]

Phase 1 Study to Evaluate the Safety and Tolerability of AB928 (Adenosine Antagonist) with AB122 (antiPD1) Immunotherapy Combinations in Participants with Advanced Malignancies [NCT03629756]

Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors [NCT03170960]

please see PHASE 1 TRIALS above

RENAL CELL CARCINOMA

Phase 1 Study to Evaluate the Safety and Tolerability of AB928 (Adenosine Antagonist) with AB122 (antiPD1) Immunotherapy Combinations in Participants with Advanced Malignancies [NCT03629756]

Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors [NCT03170960]

Phase 1 Study of BDB001 (IV TLR agonist) in Combination with Atezolizumab (PD-L1 antibody) in Subjects with Advanced Solid Tumors [NCT04196530]

please see PHASE 1 TRIALS above

SARCOMA

Phase 1/2 Study IMC-C103C (bispecific) as Single Agent or Combination with Atezolizumab (PD-L1 antibody) in HLA-A 0201-Positive Patients with Mage-A4- Positive Cancer [NCT03973333]

please see PHASE 1 TRIALS above

SQUAMOUS CELL CANCER SKIN

Phase 1 Study of REGN3767 (anti-LAG-3 mAb) Administered Alone or in Combination with REGN2810 (anti-PD-1 mAb) in Patients with Advanced Malignancies [NCT03005782]

Adjuvant Cemiplimab versus Placebo After Surgery and Radiation Therapy in Patients with High Risk Cutaneous Squamous Cell Carcinoma [NCT03969004]

Find out of you're eligible

Research & Clinical Trials Main Page

FOR FURTHER INFORMATION:

EMAIL: clinicaltrials@theangelesclinic.org

(310) 231-2185

CALL TODAY: (310) 582-7900

Currently Accruing Clinical Trials

Find out of you're eligible

Research & Clinical Trials Main Page

NEWS & EVENTS

CALL TODAY: (310) 582-7900

Currently Accruing Clinical Trials

Find out of you're eligible

Research & Clinical Trials Main Page

Footer

NEWS & EVENTS